Newlink Genetics reported $-7719000 in EBITDA for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Agenus AGEN:US $ -34.34M 20.08M
Bristol Myers Squibb BMY:US $ 5772M 404M
Capricor Therapeutics CAPR:US $ -5.94M 2.84M
Celldex Therapeutics CLDX:US $ -22.45M 2.88M
Eli Lilly And LLY:US $ 3005.6M 161.6M
Idera Pharmaceuticals IDRA:US $ -4.18M 0.06M
Intrexon XON:US $ -14.12M 3.05M
Merk MRK:US $ 6179M 492M
Nektar Therapeutics NKTR:US $ -111.36M 1.88M
Newlink Genetics NLNK:US $ -7.72M 1.16M
Pfizer PFE:US $ 11182M 4046M
Prothena PRTA:US -37744000 4.89M
Sarepta Therapeutics SRPT:US $ -76.16M 19.51M
Vascular Biogenics VBLT:US -10226000 1.45M
YTE INCY:US $ 144.1M 9.29M